FIELD: biotechnology.
SUBSTANCE: described is a group of inventions including a method for generating an immune response in a subject, directed against an antigen or an antigenic epitope dependent on CD4+ helper T cells and/or cytotoxic CD8+ T cells, and a method for generating an immune response in a subject, directed against an antigen or an antigenic epitope limited by class I MHC molecules and/or class II MHC molecules. In one of the variants of implementation, the methods include introducing to the subject (I) a modulator of immune checkpoints and (ii) a complex containing: a) a cell-penetrating peptide; b) at least one antigen or antigenic epitope; and c) at least one TLR peptide agonist, wherein the components a) to c) are covalently bound.
EFFECT: invention expands the range of means for generating an immune response in a subject.
30 cl, 40 dwg, 2 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF IMMUNE CHECKPOINT MODULATOR AND COMPLEX CONTAINING CELL-PENETRATING PEPTIDE, CARGO MOLECULE, AND TLR PEPTIDE AGONIST FOR MEDICAL USE | 2017 |
|
RU2748378C2 |
| FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| VIRUS VECTOR | 2020 |
|
RU2799418C1 |
| HUMANIZED ANTIBODY AGAINST PD-1 AND ITS USE | 2019 |
|
RU2803460C2 |
| BIFUNCTIONAL BINDING POLYPEPTIDES | 2019 |
|
RU2806747C2 |
| THERAPEUTIC RNA FOR OVARIAN CANCER | 2020 |
|
RU2832172C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
